Follow us on Twitter
twitter icon@FreshPatents


Quinoline patents

      

This page is updated frequently with new Quinoline-related patent applications.




 Indenotriphenylene-based iridium complexes for organic electroluminescence device patent thumbnailnew patent Indenotriphenylene-based iridium complexes for organic electroluminescence device
Wherein a ring represents an imidazole, a pyridine, a quinoline and an isoquinoline, x1-x2 represents a bidentate ligand, and m, n and r1 to r4 are the same definition as described in the present invention.. .

 Benzoquinoline inhibitors of vesicular monoamine transporter 2 patent thumbnailnew patent Benzoquinoline inhibitors of vesicular monoamine transporter 2
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (vmat2), pharmaceutical compositions thereof, and methods of use thereof. (formula (i)).
Auspex Pharmaceuticals, Inc.


 Combination therapy patent thumbnailnew patent Combination therapy
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog.
Aerie Pharmaceuticals, Inc.


 Method of making a benzylisoquinoline alkaloid (bia) metabolite, enzymes therefore patent thumbnailMethod of making a benzylisoquinoline alkaloid (bia) metabolite, enzymes therefore
There is provided a method of preparing a benzylisoquinoline alkaloid (bia) metabolite comprising: a. Culturing a host cell under conditions suitable for protein production, including a ph of between about 7 and about 10 said host cell comprising: b.
Valorbec SociÉtÉ En Commandite


 Compounds, compositions and associated methods comprising 3-aryl quinolines patent thumbnailCompounds, compositions and associated methods comprising 3-aryl quinolines
Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed..
The United States Government As Represented By The Department Of Veterans Affairs


 Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors patent thumbnailNovel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
The present invention is directed to novel quinoline compounds useful as s-nitrosoglutathione reductase (gsnor) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.. .
Nivalis Therapeutics, Inc.


 Therapeutic agent for ocular fundus disease patent thumbnailTherapeutic agent for ocular fundus disease
Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient..
Kowa Company, Ltd.


 Quinoline-based kinase inhibitors patent thumbnailQuinoline-based kinase inhibitors
The present disclosure is generally directed to compounds of formula (i) which can inhibit aaki (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting aaki.. .
Bristol-meyers Squibb Company


 Arylquinoline, arylquinolone and arylthioquinolone derivatives and use thereof to treat cancer patent thumbnailArylquinoline, arylquinolone and arylthioquinolone derivatives and use thereof to treat cancer
Arylquinoline derivatives and their use for treating cancer or cancer metastasis is disclosed. The compounds of the subject technology promote cells to secrete a pro-apoptotic tumor suppressor, i.e., prostate apoptosis response-4 (par-4), which in turn promote apoptosis in cancer cells or metastatic cells..
University Of Kentucky Research Foundation


 Crystalline forms of a prolyl hydroxylase inhibitor patent thumbnailCrystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
Fibrogen, Inc.


Selectively substituted quinoline compounds

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (sle) and lupus nephritis.. .
Eisai R&d Management Co., Ltd.

Compositions and methods of treating a neurodegenerative disease

The present application relates to new uses of 5-ht6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, and to the combination of 5-ht6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, with other therapeutic agents for the treatment of a neurodegenerative disease.. .
Axovant Sciences Ltd.

Methods of treating a neurodegenerative disease

The present application relates to new uses of 5-ht6 receptor antagonists, specifically high doses of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-ht6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, with, an acetylcholinesterase inhibitor for the treatment of a neurodegenerative disease.. .
Axovant Sciences, Ltd.

Pharmaceutical compositions for the treatment of cftr mediated diseases

Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (compound 1) in form i and a solid dispersion comprising substantially amorphous n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide (compound 2), methods of treating, lessening the severity of, or symptomatically treating cftr mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.. .
Vertex Pharmaceuticals Incorporated

Compositions and methods for producing benzylisoquinoline alkaloids

The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound.
California Institute Of Technology

Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors

The invention described herein pertains to substituted indenoisoquinoline compounds as described herein, wherein ra, rd, w, x and y are defined herein, pharmaceutical compositions and formulations comprising the indenoisoquinoline compounds, their synthesis, and methods for their use in the treatment and/or prevention of cancer.. .
Purdue Research Foundation

Substituted tetrahydroisoquinoline compounds as factor xia inhibitors

Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..

Substituted piperidinyl-tetrahydroquinolines

The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, raynaud's phenomenon, crest syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.. .
Bayer Pharma Aktiengesellschaft

4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. .
Glaxosmithkline Llc

Novel solution processable red-emitting iridium (iii) complex and organic electroluminescence device including the same

The present invention relates to a novel solution processable red-emitting iridium (iii) complex. In the iridium (iii) complex, a quinoline-thiophene derivative is introduced as a main ligand and a picolinic acid derivative substituted with a halogen, a substituent having electron transporting properties or a substituent having hole transporting properties is introduced as an ancillary ligand at the para-position relative to the nitrogen atom of picolinic acid.
Pusan National University Industry-university Cooperation Foundation

Compositions and methods for producing benzylisoquinoline alkaloids

The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound.
California Institute Of Technology

Substituted piperidinyltetrahydroquinolines

The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, raynaud's phenomenon, crest syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.. .
Bayer Pharma Aktiengesellschaft

Quinoline derivatives as pde10a enzyme inhibitors

The present invention provides quinoline derivatives of formula i that are pde10a enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for pde10a over other pde subtypes.
H. Lundbeck A/s

Novel quinoline derivatives and their use in neurodegenerative diseases

The present invention relates to quinoline compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of p2x7, and for the treatment of p2x7-related disorders.. .
Merck Patent Gmbh

Pyridinylpyrazoloquinoline compounds

And r2 represents a 3-methyltetrahydro-2h-pyran-4-yl group or 4-methoxycyclohexyl group.. .

Substituted tetrahydroisoquinoline compounds as factor xia inhibitors

Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..

Methods for the treatment of abnormal involuntary movement disorders

Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.. .
Auspex Pharmaceuticals, Inc.

Alkoxy substituted imidazoquinolines

Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.. .
3m Innovative Properties Company

5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

The present invention relates to novel quinoline compounds of formula (i), and their pharmaceutically acceptable salts and process for their preparation. The compounds of formula (i) are useful in the treatment of various disorders that are related to 5-ht4 receptor agonists..
Suven Life Sciences Limited

6-aminoisoquinoline compounds

6-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided.
Aerie Pharmaceuticals, Inc.

Quinolines derivatives as novel anticancer agents

The invention provides quinoline derivatives, their manufacture, pharmaceutical compositions containing them, and their use as medicaments. The active compounds of the present invention are useful for the treatment of proliferative neoplastic and non-neoplastic diseases..
Genoscience Pharma

Arylquinoline and analog compounds and use thereof to treat cancer

The subject technology relates to arylquinoline compounds and their use for treating cancer or cancer metastasis. The compounds of the subject technology promote cells to secrete a pro-apoptotic tumor suppressor, i.e., prostate apoptosis response-4 (par-4), which in turn promote apoptosis in cancer cells or metastatic cells..
University Of Kentucky Research Foundation

Ligands of the benzo [h] quinoline class and transition metal complexes containing them and use of said complexes as catalysts

A new class of ligands derived from benzo[h]quinoline are described and these ligands are used to prepare several novel transition metal complexes. The complexes are preferably of the group viii transition metals iron, ruthenium or osmium, with the benzo[h]quinolone ligands acting as tridentate ligands.
Universita' Degli Studi Di Udine

5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof

The subject invention provides 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, its salts and uses.. .
Teva Pharmaceutical Industries, Ltd.

Anthropod repellent chemicals

Compositions and methods for repelling arthropods. The compositions include a carrier and an arthropod repelling compound, which can be a compound discovered by a novel and complex cheminformatic process to demonstrate repellency behavior across a broad spectrum of arthropods.
The Regents Of The University Of California

Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline

Wherein the variables r1, r2, r3, r4, and m are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (hsd) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia..

Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde 10a)

Or a pharmaceutically acceptable salt thereof, wherein r′, r1 through r7 and ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (pde10a) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type ii diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases..

Organic electroluminescent materials and devices

Novel ligands for metal complexes, where the ligands contain fused carbo or heterocycles on the quinoline building block are disclosed. More extended aromaticity within the molecule allows red shift when the molecules are used as light emitting dopants in organic light emitting diodes/devices..
Universal Display Corporation

Tetrahydroquinoline compositions as bet bromodomain inhibitors

Wherein w, x, y, z, r1, r2, r5, and r8 are as described herein.. .

Aminoisoquinoline derivatives as protein kinase inhibitors

The present invention provides novel aminoisoquinoline compounds as defined in the specification, compositions thereof use of these compounds as protein kinase inhibitors and as therapeutic agents for treatment of raf kinase, in particular brafv600e kinase, related diseases or disorders, such as cancers. In addition, the invention also includes methods and processes for preparing these novel aminoisoquinoline compounds..
Eternity Bioscience Inc.

Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity

Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride.. .
Cti Biopharma Corp.

H3 receptor antagonist for use in the treatment of alzheimer's disease

The disclosure relates to the compound 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof, intended for the treatment of alzheimer's disease and other types of dementia.. .
Sanofi

Tetrahydroquinoline compositions as bet bromodomain inhibitors

Wherein w, x, y, z, r1, r2, r5, and r8 are as described herein.. .

Benzylisoquinoline alkaloid (bia) precursor producing microbes, and methods of making and using the same

Host cells that are engineered to produce benzylisoquinoline alkaloid (bias) precursors, such as norcoclaurine (nc) and norlaudanosoline (nl), are provided. The host cells may have one or more engineered modifications selected from: a feedback inhibition alleviating mutation in a enzyme gene; a transcriptional modulation modification of a biosynthetic enzyme gene; an inactivating mutation in an enzyme; and a heterologous coding sequence.
The Board Of Trustees Of The Leland Stanford Junior University



Quinoline topics:
  • Isoquinolin
  • Praziquantel
  • Carbon Atoms
  • Crystallin
  • Quinoline Derivatives
  • Pharmaceutically Acceptable Salt
  • Alkyl Group
  • Cycloalkyl
  • Pharmaceutically Acceptable Salts
  • Immunodeficiency
  • Retrovirus
  • Viral Infection
  • Human Immunodeficiency Virus
  • Angiogenesis
  • Sulfonamide


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Quinoline for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Quinoline with additional patents listed. Browse our RSS directory or Search for other possible listings.


    2.7976

    file didn't exist2371

    469974 - 0 - 51